Hepatology
Innovative liver disease treatments addressing acute and chronic hepatic conditions
Liver Disease Innovation
Oracle BioTech develops cutting-edge therapies for liver diseases including viral hepatitis, non-alcoholic fatty liver disease, cirrhosis, and hepatocellular carcinoma.

Viral Hepatitis
Advanced antiviral therapies for hepatitis B and C with improved cure rates and shorter treatment durations.
- Direct-acting antivirals
- Hepatitis B cure research
- Combination therapy regimens
- Resistance barrier enhancement

NASH & Liver Fibrosis
Novel treatments for non-alcoholic steatohepatitis and liver fibrosis targeting multiple disease pathways.
- NASH progression inhibitors
- Anti-fibrotic agents
- Metabolic pathway modulators
- Liver regeneration therapy
Hepatology Pipeline
Discovery
7 ProgramsNovel liver-specific targets and mechanisms.
Preclinical
5 ProgramsLiver disease models and hepatotoxicity studies.
Phase I
3 ProgramsSafety studies in liver disease patients.
Phase II
2 ProgramsEfficacy studies in NASH and hepatitis B.
Approved
1 ProductFDA-approved hepatitis C treatment.